Table 4.
Antithrombosis strategy by risk factor clustering
| Anticoagulation strategy by trimester | N used | Overall (N=108) | No risk factors (N=47) | 1 risk factor (N=33) | 2+ risk factors (N=28) | P value |
|---|---|---|---|---|---|---|
| Pre-pregnancy | 108 | 0.071 | ||||
| None | 53 (49.1%) | 28 (59.6%) | 16 (48.5%) | 9 (32.1%) | ||
| Aspirin | 23 (21.3%) | 7 (14.9%) | 11 (33.3%) | 5 (17.9%) | ||
| Prophylactic heparin* | 1 (0.9%) | 1 (2.1%) | 0 (0.0%) | 0 (0.0%) | ||
| VKA† | 28 (25.9%) | 10 (21.3%) | 6 (18.2%) | 12 (42.9%) | ||
| Combo‡ | 3 (2.8%) | 1 (2.1%) | 0 (0.0%) | 2 (7.1%) | ||
| Aspirin during pregnancy | 108 | 0.40 | ||||
| No | 54 (50.0%) | 21 (44.7%) | 16 (48.5%) | 17 (60.7%) | ||
| Yes | 54 (50.0%) | 26 (55.3%) | 17 (51.5%) | 11 (39.3%) | ||
| VKA† during pregnancy | 108 | 0.47 | ||||
| No | 93 (86.1%) | 42 (89.4%) | 29 (87.9%) | 22 (78.6%) | ||
| Yes | 15 (13.9%) | 5 (10.6%) | 4 (12.1%) | 6 (21.4%) | ||
| Treatment heparin during pregnancy | 108 | 0.13 | ||||
| NA/unknown | 65 (60.2%) | 30 (63.8%) | 22 (66.7%) | 13 (46.4%) | ||
| Prophylactic heparin* | 21 (19.4%) | 5 (10.6%) | 7 (21.2%) | 9 (32.1%) | ||
| Therapeutic heparin* | 22 (20.4%) | 12 (25.5%) | 4 (12.1%) | 6 (21.4%) | ||
| First trimester | 108 | 0.33 | ||||
| None | 26 (24.1%) | 11 (23.4%) | 10 (30.3%) | 5 (17.9%) | ||
| Aspirin | 47 (43.5%) | 23 (48.9%) | 15 (45.5%) | 9 (32.1%) | ||
| Prophylactic heparin* | 12 (11.1%) | 3 (6.4%) | 3 (9.1%) | 6 (21.4%) | ||
| Therapeutic heparin* | 13 (12.0%) | 6 (12.8%) | 1 (3.0%) | 6 (21.4%) | ||
| VKA† | 6 (5.6%) | 3 (6.4%) | 2 (6.1%) | 1 (3.6%) | ||
| Combo‡ | 4 (3.7%) | 1 (2.1%) | 2 (6.1%) | 1 (3.6%) | ||
| Second trimester | 108 | 0.14 | ||||
| None | 26 (24.1%) | 11 (23.4%) | 11 (33.3%) | 4 (14.3%) | ||
| Aspirin | 38 (35.2%) | 20 (42.6%) | 9 (27.3%) | 9 (32.1%) | ||
| Prophylactic heparin* | 14 (13.0%) | 2 (4.3%) | 7 (21.2%) | 5 (17.9%) | ||
| Therapeutic heparin* | 12 (11.1%) | 8 (17.0%) | 1 (3.0%) | 3 (10.7%) | ||
| VKA† | 8 (7.4%) | 2 (4.3%) | 2 (6.1%) | 4 (14.3%) | ||
| Combo‡ | 10 (9.3%) | 4 (8.5%) | 3 (9.1%) | 3 (10.7%) | ||
| Third trimester | 93 | 0.52 | ||||
| None | 25 (26.9%) | 9 (22.5%) | 11 (35.5%) | 5 (22.7%) | ||
| Aspirin | 31 (33.3%) | 16 (40.0%) | 8 (25.8%) | 7 (31.8%) | ||
| Prophylactic heparin* | 10 (10.8%) | 2 (5.0%) | 4 (12.9%) | 4 (18.2%) | ||
| Therapeutic heparin* | 18 (19.4%) | 11 (27.5%) | 4 (12.9%) | 3 (13.6%) | ||
| VKA† | 3 (3.2%) | 1 (2.5%) | 1 (3.2%) | 1 (4.5%) | ||
| Combo‡ | 6 (6.5%) | 1 (2.5%) | 3 (9.7%) | 2 (9.1%) |
Values are N (%).
*
Heparin here refers to either unfractionated heparin or low molecular weight heparin.
†
Vitamin K antagonist.
‡
Combination of anticoagulation medicines.